erythropoietin drug market Market Analysis

Global Erythropoietin Drugs Market Overview

Erythropoietin Drugs Market Size was valued at USD 10.56 billion in 2023. The erythropoietin drugs market industry is projected to grow from USD 11.74 Billion in 2024 to USD 24.6 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.68% during the forecast period (2024 - 2032).EPO medications are becoming increasingly popular, often referred to as EPO stimulating agents (ESAs). They are manufactured synthetically utilizing recombinant deoxyribonucleic acid (DNA) technology. They are typically injected intramuscularly and released into the bloodstream to promote RBC formation. They are currently offered in a variety of forms with varied dosing regimens and administration methods. EPO medications are typically prescribed to patients who are receiving chemotherapy, have chronic renal failure, are on antiviral medication, or are at a high risk of bleeding excessively during surgery, contributing in the growth of the erythropoietin drugs market. These are just a few of the market drivers that are driving the market. 

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Erythropoietin Drugs Market Trends

• Rising investment in research and development of new drugs to propel market growth

The main factor compelling the expansion of the erythropoietin market is the rise in anemic conditions caused by chemotherapy, antiretroviral treatment (ART), and end-stage renal disease treatment. As a result, the demand for EPO has increased due to the number of chemotherapy treatment cycles and the incidence of end-stage renal illness (dialysis). The extended period of EPO treatment (4-6 weeks) and related side effects such as arterial hypertension, iron insufficiency, and influenza-like syndrome limit the market growth for erythropoietin medications. Moreover, rising commercialization trends for erythropoietin biosimilars, easily accessible reimbursements, supportive governmental laws, and rising public knowledge of the advantages of EPO therapies all contribute to the market's expansion. Thus, this factor is driving the market CAGR.

Erythropoietin (EPO), a medication for anemia, has been shown by researchers at the Max Planck Institute for Experimental Medicine in Göttingen to be effective against COVID-19. They claim that the growth component of erythropoietin can prevent serious sickness from developing and shield patients from long-term neurological effects when the SARS-CoV-2 attacks the brain. Primary case studies point to erythropoietin's beneficial effects. A randomized clinical trial is now being planned by researchers to comprehensively examine the effects of treating COVID-19 with erythropoietin. It is a hormone/cytokine primarily produced by the kidneys through the principal transcription factor hypoxia-inducible factor-2 and the prevention of RBC precursor apoptosis.

However, EPO has additional advantageous cytoprotective properties, such as anti-ischemic, regenerative, and anti-apoptotic actions in a range of tissues, including the lung, kidney, cardiac muscle, neurological system, retina, pancreas, and endothelial cells. It transmits its protective effects following trauma in critically ill patients via a unique receptor called EPOR-cR. Thus, it is anticipated that this aspect will accelerate erythropoietin drugs market revenue globally.

Erythropoietin Drugs Market Segment Insights

Erythropoietin Drugs Product Type Insights

The erythropoietin drugs market segmentation, based on product type, includes biosimilars, first generation formulation and second-generation formulation. The biosimilars segment held the majority share in 2022 in the erythropoietin drugs market dataDue to the expiration of several significant U.S. patents on patented medicines, the biosimilars market is anticipated to grow profitably over the forecast period. Biosimilars are already more widely used in the European and APAC markets. Aranesp (darbepoetin) and Mircera are two popular erythropoietin medications whose patents will expire during the prediction (PEG-EPO). By May 2024, the business might lose its drug's patent protection (U.S.). Furthermore, the drug's patent expiration creates fresh prospects for biosimilar manufacturers to create and market their goods.

Figure 1: Erythropoietin Drugs Market, by Product Type, 2023 & 2032 (USD Billion) 

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Erythropoietin Drugs Application Insights

The erythropoietin drugs market segmentation, based on application, includes oncology, renal diseases, and HIV. The renal diseases segment dominated the market growth in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. This dominance can be linked to the accessibility of erythropoietin medications for treating individuals with various forms of renal illness. The erythropoietin medications Epogen, Aranesp, Venofer, and Ferrlecit are a few examples. According to the Medicare and Beneficiary report, these medications account for around 25% of all prescription payments for treating anemia in CKD patients. As a result, the market for erythropoietin drugs is anticipated to be driven by well-established reimbursement policies for kidney transplants and associated disorders.

Erythropoietin Drugs End-User Insights

The erythropoietin drugs market data, based on product end-user, includes hospitals, and pharmacy. The hospital segment held the majority share in 2022 in the erythropoietin drugs market revenue. The dominance of the hospital segment can be contributed to the availability and accessibility to erythropoietin drugs. Although the hospital segment held the largest share of the market, pharmacy and especially online pharmacy are rapidly growing as the result of consumer awareness and ease of use. Thus, driving the segment of the erythropoietin drugs market.

Erythropoietin Drugs Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America Erythropoietin Drugs market accounted for USD 3.75 billion in 2022 with a share of around 45.80% and is expected to exhibit a significant CAGR growth during the study period. It can be attributed to the rising prevalence of chronic diseases like cancer, CKD, and HIV. 1.2 million Americans live with HIV, and more than 39,000 new cases were found in 2015, according to data from the Centers for Disease Control and Prevention (CDC). These figures show strong evidence that demand for EPO medications will rise over the foreseeable period. New product development, partnerships, partnerships, expansions, mergers, and acquisitions are the main strategies used by the organizations in the market.

Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: ERYTHROPOIETIN DRUGS MARKET SHARE BY REGION 2023 (%) 

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe’s Erythropoietin Drugs market accounts for the second-largest market share. Due to the rising prevalence of chronic kidney disease among patients, Europe has a developed healthcare system, and many erythropoietin medication clinical studies are being carried out. Moreover, UK Erythropoietin Drugs market held the largest market share, and the Germany erythropoietin drugs market was the fastest-growing market in the region.

Asia Pacific Erythropoietin Drugs Market is expected to grow at the fastest CAGR from 2024 to 2032. The presence of major companies in the market and their strategic efforts to create and promote novel erythropoietin medication products to treat anemia patients are credited with the region's growth. Further, the China Erythropoietin Drugs market held the largest market share, and the India Erythropoietin Drugs market was the fastest growing market in the region.

Erythropoietin Drugs Key Market Players & Competitive Insights

Major market players are spending a lot of money on R&D to increase their product lines, which will help the Erythropoietin Drugs market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, mergers and acquisitions, contractual agreements, increased investments, and collaboration with other organizations. Competitors in the erythropoietin drugs industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

One of the primary business strategies adopted by manufacturers in the erythropoietin drugs industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, Erythropoietin Drugs industry has provided medicine with some of the most significant benefits. The Erythropoietin Drugs market major player such as Hoffmann-La Roche, Johnson & Johnson, Amgen, Kyowa Hakko Kirin, Intas Pharmaceuticals, Teva Pharmaceutical Industries Ltd.

Amgen Inc. is a multi-national biopharmaceutical business with its main office in Thousand Oaks, California. Amgen, one of the biggest independent biotechnology firms in the world, was founded in 1980 in Thousand Oaks, California. Amgen's patent for Epogen impacted manufacturing and provided them with fantastic possibilities to invest in leading companies.

An international pharmaceutical firm based in Israel; Teva Pharmaceutical Industries Ltd. has its corporate office in Tel Aviv. Generic medications are its main area of expertise, but it also has certain additional business interests in active pharmaceutical ingredients and, to a lesser extent, patented drugs. The most prominent distributor in the United States region, Anda, was introduced by Teva Pharma in October 2016 and has strengthened the company's distribution network infrastructure.

Key Companies in the Erythropoietin Drugs market includes

• Hoffmann-La Roche


• Johnson & Johnson


• Amgen


• Kyowa Hakko Kirin


• Intas Pharmaceuticals


• Biocon


• Emcure Pharmaceuticals


• Celltrion Inc.


• Hospira


• Teva Pharmaceutical Industries Ltd.